150 related articles for article (PubMed ID: 21206384)
1. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer.
Subramanian J; Corrales L; Soulieres D; Morgensztern D; Govindan R
J Thorac Oncol; 2011 Feb; 6(2):399-403. PubMed ID: 21206384
[TBL] [Abstract][Full Text] [Related]
2. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010).
Stinchcombe TE; Baggstrom MQ; Somaiah N; Simon GR; Govindan R
J Thorac Oncol; 2011 Jan; 6(1):227-32. PubMed ID: 21178721
[TBL] [Abstract][Full Text] [Related]
3. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
Morgensztern D; Pennell NA; Subramanian J; Govindan R
Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555
[TBL] [Abstract][Full Text] [Related]
4. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
5. Summary of presentations from the 11th targeted therapies for lung cancer meeting: radiation oncology.
Iyengar P; Choy H
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1822-4. PubMed ID: 22005545
[No Abstract] [Full Text] [Related]
6. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
7. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
8. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
9. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic and therapeutic biomarkers for lung cancer patients].
Seike M; Gemma A
Nihon Rinsho; 2012 May; 70(5):809-15. PubMed ID: 22620005
[TBL] [Abstract][Full Text] [Related]
13. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
[TBL] [Abstract][Full Text] [Related]
14. Mesothelioma and small cell lung cancer.
Tsao AS; Heymach J
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1825-6. PubMed ID: 22005546
[No Abstract] [Full Text] [Related]
15. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
16. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
Cottini F; Lautenschlaeger T
Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
18. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
Gadgeel SM
Adv Exp Med Biol; 2016; 890():203-22. PubMed ID: 26703806
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
Perez CA; Velez M; Raez LE; Santos ES
Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
